The Brain's Cannabis System Changes With Age — And May Hold Keys to Fighting Neurodegeneration | Research

The takeaway

A comprehensive review shows the endocannabinoid system deteriorates with normal aging and more severely in neurodegenerative diseases, but some changes may be the brain's attempt to protect itself.

Older adults, neurodegeneration researchers, geriatric medicine specialists, and anyone interested in brain aging and cannabinoid science.

What the researchers found

Normal aging shows CB1 receptor downregulation and increased endocannabinoid-degrading enzymes, contributing to cognitive and motor decline. In neurodegenerative diseases, these changes become extreme. However, elevated endocannabinoid levels (from reduced FAAH/MAGL) and CB2 receptor upregulation may represent protective compensatory responses. Pharmacological targeting of specific ECS components shows neuroprotective potential.

Why it matters

As global lifespans increase, neurodegenerative diseases are expanding. Understanding how the brain's endocannabinoid system changes with age could lead to interventions that slow cognitive decline and protect against diseases like Alzheimer's and Parkinson's.

The numbers in context

Changes documented across: CB1 receptor downregulation, FAAH/MAGL expression changes, CB2 receptor upregulation (compensatory), endocannabinoid level alterations. Disorders covered: Alzheimer's, Parkinson's, Huntington's, ALS, and general age-related cognitive decline.

How the study worked

Comprehensive narrative review synthesizing 30-40 years of research on the endocannabinoid system across the lifespan, from neurodevelopment through senescence. Covers normal aging changes and their extreme presentation in neurodegenerative disorders, with discussion of therapeutic implications.

What this study cannot tell us

Narrative review spans decades of research with varying methodologies. Animal models may not perfectly reflect human aging. Translation from basic science to clinical therapy remains challenging. Individual variation in aging and ECS function is large.

How to read the evidence

Comprehensive multi-decade review with consistent findings, though primarily based on preclinical evidence with limited clinical validation.

When this study was published

Published in 2026, timely as the aging global population faces increasing neurodegenerative disease burden.

The bigger picture

The dual nature of ECS changes in aging is fascinating: some changes contribute to decline while others protect against it. This suggests that nuanced pharmacological approaches — boosting protective components while addressing harmful ones — could be more effective than blanket cannabinoid therapy.

Questions still open

Could monitoring ECS changes predict neurodegeneration risk? Would targeted ECS therapies slow normal cognitive aging? At what age might preventive ECS-based interventions be most effective?

Common questions

Does the brain's cannabis system change with age?

Yes — CB1 receptors decline, enzymes that break down endocannabinoids increase, and overall endocannabinoid signaling weakens. These changes contribute to age-related cognitive and motor decline, but the brain also makes protective compensatory adjustments.

Could cannabinoids prevent age-related brain decline?

Potentially. Targeting specific ECS components — like boosting endocannabinoid levels or activating CB2 receptors — shows neuroprotective effects in animal studies. But translating this to safe, effective human therapies remains a major challenge.

Read the original research

Ageing, Neurodegeneration and the Endocannabinoid System.

Current topics in behavioral neurosciences, 76, 209-248

View on PubMed ↗Publisher’s paper ↗

Citation

Fernández-Ruiz, Javier; Sagredo, Onintza; Gómez-Ruiz, María; de Lago, Eva. (2026). Ageing, Neurodegeneration and the Endocannabinoid System.. Current topics in behavioral neurosciences, 76, 209-248. https://doi.org/10.1007/7854_2025_597